Katrien Remaut - Nanotechnology

Author Information

Katrien Remaut is a researcher affiliated with the Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy at Ghent University, as well as the Cancer Research Institute Ghent (CRIG) at Ghent University Hospital, both located in Ghent, Belgium. Her work primarily focuses on the field of nanotechnology, with a particular emphasis on nanomedicine and its applications in cancer treatment and drug delivery systems.

Research Contributions

Katrien Remaut has made significant contributions to the field of nanotechnology, particularly in the development of nanomedicines for therapeutic applications. Her research encompasses a range of innovative approaches, including the use of laser-induced nanobubbles for the safe ablation of vitreous opacities, nanoparticle-mediated targeting for cancer treatment, and strategies for controlling immune activity in mRNA therapeutics. She has also explored the use of lipoplexes for oligonucleotide delivery in bacterial infections and the application of high-pressure nebulization for drug delivery. Her work has been instrumental in advancing our understanding of nanoparticle interactions with biological systems and improving therapeutic outcomes in diverse medical conditions.

Aliases

Katrien Remaut is also known by the aliases K Remaut and K. Remaut. These variations are commonly used in academic publications and citations.

Publication and Citation Metrics

Metric	Value
Citation Count	3616
H-index	34
Paper Count	141

Publications:

Laser-induced nanobubbles safely ablate vitreous opacities in vivo

DOI: 10.1038/s41565-022-01086-4

Year: 2022

Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer.

DOI: 10.1016/j.ejpb.2022.01.002

Year: 2022

Together is Better: mRNA Co‐Encapsulation in Lipoplexes is Required to Obtain Ratiometric Co‐Delivery and Protein Expression on the Single Cell Level

DOI: 10.1002/advs.202102072

Year: 2021

Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across

DOI: 10.1016/j.addr.2021.113900

Year: 2021

Vaccinia Virus Protein B18R: Influence on mRNA Immunogenicity and Translation upon Non-Viral Delivery in Different Ocular Cell Types

DOI: 10.3390/pharmaceutics13010074

Year: 2021

Lipoplexes to Deliver Oligonucleotides in Gram-Positive and Gram-Negative Bacteria: Towards Treatment of Blood Infections

DOI: 10.3390/pharmaceutics13070989

Year: 2021

Exploring High Pressure Nebulization of Pluronic F127 Hydrogels for Intraperitoneal Drug Delivery.

DOI: 10.1016/j.ejpb.2021.10.001

Year: 2021

Electrostatic Intraperitoneal Aerosol Delivery of Nanoparticles: Proof of Concept and Preclinical Validation

DOI: 10.1002/adhm.202000655

Year: 2020

Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion

DOI: 10.1080/17425247.2020.1736551

Year: 2020

Nanomaterials to avoid and destroy protein aggregates

DOI: 10.1016/j.nantod.2019.100837

Year: 2020

How Are Donations Utilized in Nanotechnology?

How Does Mechanical Exfoliation Work?

How Do Targeting Agents Work?

What Challenges are Faced in the Clinical Translation of Nanotechnology?

What are some tips for securing funding in nanotechnology?

How Do Hydrophobic Effects Influence Nanomaterial Properties?

How to Properly Use a Fume Hood in Nanotechnology?

How Does the Lotus Effect Work?

What is Fluidic Resistance?

How Can Nanotechnology Improve Recycling?

Partnered Content Networks

Relevant Topics